FNDC5 and sarcopenia: The differences in the levels of these biomarkers between the sarcopenia and non-sarcopenia groups that were observed at baseline pre-intervention were mostly reduced after 6 months of intervention, resulting in comparable levels of biomarkers of muscle metabolism (creatinine; irisin) and insulin signaling (c-peptide; insulin; leptin).